Description: Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Home Page: www.savarapharma.com
Building III
Austin,
TX
78746
United States
Phone:
512 614 1848
Officers
| Name | Title |
|---|---|
| Mr. Matthew Pauls | Chairman & CEO |
| Mr. David L. Lowrance CPA | CFO & Sec. |
| Ms. Kate McCabe | Sr. VP of Legal Affairs |
| Ms. Anne Erickson | Sr. VP & Head of Global Bus. Operations |
| Brian Maurer | Head of Clinical Operations |
| Mr. Charles LaPree | Sr. VP of Global Regulatory Affairs & Quality Assurance |
| Dr. Peter Clarke Ph.D. | Exec. VP of Global Technical Operations |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5572 |
| Price-to-Sales TTM: | 127839.36 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |